Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects With Normal or Varying Degrees of Impaired Renal Function

Drugs in R and D - United Kingdom
doi 10.1007/s40268-014-0066-4
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function

Clinical Pharmacology in Drug Development
PharmacologyPharmaceutical Science
2019English

Single-Dose Pharmacokinetics and Safety of Daclatasvir in Subjects With Renal Function Impairment

Antiviral Therapy
Infectious DiseasesPharmacology
2015English

Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects With Normal or Impaired Hepatic Function

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2000English

Pharmacokinetics of Ceftizoxime in Subjects With Various Degrees of Renal Function.

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1983English

Pharmacokinetics of Cefamandole in Patients With Normal and Impaired Renal Function

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1977English

Pharmacokinetics of Moxalactam in Subjects With Various Degrees of Renal Dysfunction.

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1980English

Pharmacokinetics of Felodipine in Patients With Impaired Renal Function.

British Journal of Clinical Pharmacology
Pharmacology
1989English

The Pharmacokinetics and Safety of Darapladib in Subjects With Severe Renal Impairment

British Journal of Clinical Pharmacology
Pharmacology
2015English

Pharmacokinetics and Safety of Enasidenib Following Single Oral Doses in Japanese and Caucasian Subjects

Pharmacology Research and Perspectives
ToxicologyNeurologyPharmaceuticsPharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy